Belongs to

• Center for Hematologic Malignancies

Types of Work

["2022"]

[[["Meeting Abstracts",442],["Journal Articles",322],["Reviews",28],["Research Letters",14],["Book Sections",10],["Guidelines",7],["Correspondences",6],["Editorials",4],["Conference Papers",1]]]

[834]

Popular keywords

• adult
• aged
• article
• controlled study
• female
• human
• humans
• male
• multiple myeloma
• priority journal

Recent Works

1. Efficacy and safety of elranatamab by age and frailty in patients with relapsed/refractory multiple myeloma (RRMM): Subgroup analysis from MagnetisMM-3

   Meeting Abstract

   Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
   Clinical Lymphoma, Myeloma and Leukemia (2023)

   Fulltext@MSK | Save
2. Belantamab mafodotin for relapsed or refractory multiple myeloma: A real-world observational study update

   Meeting Abstract

   Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Happ, L. P.; more...
   Clinical Lymphoma, Myeloma and Leukemia (2023)

   Fulltext@MSK | Save
3. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies

   Meeting Abstract

   Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
   Clinical Lymphoma, Myeloma and Leukemia (2023)

   Fulltext@MSK | Save